"Dec. 20, 2010 -- New research suggests that one out of every 200 patients being treated with gastric acid-suppressive drugs for heartburn and other conditions may develop pneumonia.
Researchers led by Chun-Sick Eom, MD, MPH, from Seoul "...
Treatment Of Gastroesophageal Reflux Disease (GERD)
Healing of Erosive Esophagitis
NEXIUM is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of NEXIUM may be considered.
In infants 1 month to less than 1 year, NEXIUM is indicated for short-term treatment (up to 6 weeks) of erosive esophagitis due to acid-mediated GERD.
Maintenance of Healing of Erosive Esophagitis
NEXIUM is indicated to maintain symptom resolution and healing of erosive esophagitis. Controlled studies do not extend beyond 6 months.
Symptomatic Gastroesophageal Reflux Disease
NEXIUM is indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with GERD in adults and children 1 year or older.
Risk Reduction Of NSAID-Associated Gastric Ulcer
NEXIUM is indicated for the reduction in the occurrence of gastric ulcers associated with continuous NSAID therapy in patients at risk for developing gastric ulcers. Patients are considered to be at risk due to their age ( > 60) and/or documented history of gastric ulcers. Controlled studies do not extend beyond 6 months.
H. pylori Eradication To Reduce The Risk Of Duodenal Ulcer Recurrence
Triple Therapy (NEXIUM plus amoxicillin and clarithromycin): NEXIUM, in combination with amoxicillin and clarithromycin, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see DOSAGE AND ADMINISTRATION and Clinical Studies].
In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see CLINICAL PHARMACOLOGY and the prescribing information for clarithromycin].
Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome
NEXIUM is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison Syndrome.
DOSAGE AND ADMINISTRATION
NEXIUM is supplied as delayed-release capsules for oral administration or in packets for preparation of delayed-release oral suspensions. The recommended dosages are outlined in Table 1. NEXIUM should be taken at least one hour before meals.
The duration of proton pump inhibitor administration should be based on available safety and efficacy data specific to the defined indication and dosing frequency, as described in the prescribing information, and individual patient medical needs. Proton pump inhibitor treatment should only be initiated and continued if the benefits outweigh the risks of treatment.
Table 1: Recommended Dosage Schedule of NEXIUM
|Gastroesophageal Reflux Disease (GERD)|
|Healing of Erosive Esophagitis||20 mg or 40 mg||Once Daily for 4 to 8 Weeks*|
|Maintenance of Healing of Erosive Esophagitis||20 mg||Once Daily|
|Symptomatic Gastroesophageal Reflux Disease||20 mg||Once Daily for 4 Weeks***|
|12 to 17 Year Olds|
|Healing of Erosive Esophagitis||20 mg or 40 mg||Once Daily for 4 to 8 Weeks|
|Symptomatic GERD||20 mg||Once Daily for 4 Weeks|
|1 to 11 Year Olds+|
|Short-term Treatment of Symptomatic GERD||10 mg||Once Daily for up to 8 Weeks|
|Healing of Erosive Esophagitis|
|weight < 20 kg||10 mg||Once Daily for 8 Weeks|
|weight ≥ 20 kg||10 mg or 20 mg||Once Daily for 8 Weeks|
|1 month to < 1 year old***|
|Erosive esophagitis due to acid-mediated GERD|
|weight 3 kg to 5 kg||2.5 mg||Once Daily for up to 6 Weeks|
|weight > 5 kg to 7.5 kg||5 mg||Once Daily for up to 6 Weeks|
|weight > 7.5 kg to 12 kg||10 mg||Once Daily for up to 6 Weeks|
|Risk Reduction of NSAID-Associated Gastric Ulcer||20 mg or 40 mg||Once Daily for up to 6 months**|
|H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence|
|NEXIUM||40 mg||Once Daily for 10 Days|
|Amoxicillin||1000 mg||Twice Daily for 10 Days|
|Clarithromycin||500 mg||Twice Daily for 10 Days|
|Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome||40 mg†||‡Twice Daily|
|*[See Clinical Studies] The majority of
patients are healed within 4 to 8 weeks. For patients who do not heal after 4
to 8 weeks, an additional 4 to 8 weeks of treatment may be considered.
**Controlled studies did not extend beyond six months.
***If symptoms do not resolve completely after 4 weeks, an additional 4 weeks of treatment may be considered. +Doses over 1 mg/kg/day have not been studied.
†The dosage of NEXIUM in patients with pathological hypersecretory conditions varies with the individual patient. Dosage regimens should be adjusted to individual patient needs.
‡Doses up to 240 mg daily have been administered [see DRUG INTERACTIONS].
‡‡‡Doses over 1.33 mg/kg/day have not been studied.
Please refer to amoxicillin and clarithromycin prescribing information for Contraindications, Warnings, and dosing in elderly and renally-impaired patients.
In patients with mild to moderate liver impairment (Child Pugh Classes A and B), no dosage adjustment is necessary. For patients with severe liver impairment (Child Pugh Class C), a dose of 20 mg of NEXIUM should not be exceeded [see CLINICAL PHARMACOLOGY].
Directions for use specific to the route and available methods of administration for each of these dosage forms are presented in Table 2.
Table 2: Administration Options
|Administration Options (See text following table for additional instructions.)|
|Delayed-Release Capsules||Oral||Capsule can be swallowed whole. -or- Capsule can be opened and mixed with applesauce.|
|Delayed-Release Capsules||Nasogastric Tube||Capsule can be opened and the intact granules emptied into a syringe and delivered through the nasogastric tube.|
|For Delayed-Release Oral Suspension||Oral||For the 2.5 mg and 5 mg strengths, mix the contents of packet with 5 mL of water, leave 2 to 3 minutes to thicken, stir and drink within 30 minutes. For the 10 mg, 20 mg and 40 mg strengths, mix contents of packet with 15 mL of water, and follow the instructions above.|
|For Delayed-Release Oral Suspension||Nasogastric or Gastric Tube||For the 2.5 mg and 5 mg strengths, add 5 mL of water to a syringe and then add contents of packet. Shake the syringe; leave 2 to 3 minutes to thicken. Shake the syringe and inject through the nasogastric or gastric tube within 30 minutes. For the 10 mg, 20 mg and 40 mg strengths, add 15 mL of water, and follow the instructions above.|
NEXIUM Delayed-Release Capsules
NEXIUM Delayed-Release Capsules should be swallowed whole.
Alternatively, for patients who have difficulty swallowing capsules, one tablespoon of applesauce can be added to an empty bowl and the NEXIUM Delayed-Release Capsule can be opened, and the granules inside the capsule carefully emptied onto the applesauce. The granules should be mixed with the applesauce and then swallowed immediately: do not store for future use. The applesauce used should not be hot and should be soft enough to be swallowed without chewing. The granules should not be chewed or crushed. If the granules/applesauce mixture is not used in its entirety, the remaining mixture should be discarded immediately.
For patients who have a nasogastric tube in place, NEXIUM Delayed-Release Capsules can be opened and the intact granules emptied into a 60 mL catheter tipped syringe and mixed with 50 mL of water. It is important to only use a catheter tipped syringe when administering NEXIUM through a nasogastric tube. Replace the plunger and shake the syringe vigorously for 15 seconds. Hold the syringe with the tip up and check for granules remaining in the tip. Attach the syringe to a nasogastric tube and deliver the contents of the syringe through the nasogastric tube into the stomach. After administering the granules, the nasogastric tube should be flushed with additional water. Do not administer the granules if they have dissolved or disintegrated.
The mixture must be used immediately after preparation.
NEXIUM For Delayed-Release Oral Suspension
NEXIUM For Delayed-Release Oral Suspension should be administered as follows:
- Empty the contents of a 2.5 mg or 5 mg packet into a container containing 5 mL of water. For the 10 mg, 20 mg, and 40 mg strengths, the contents of a packet should be emptied into a container containing 15 mL of water.
- Leave 2 to 3 minutes to thicken.
- Stir and drink within 30 minutes.
- If any medicine remains after drinking, add more water, stir, and drink immediately.
- In cases where there is a need to use two packets, they may be mixed in a similar way by adding twice the required amount of water or follow the mixing instructions provided by your pharmacist or doctor.
For patients who have a nasogastric or gastric tube in place, NEXIUM For Delayed-Release Oral Suspension can be administered as follows:
- Add 5 mL of water to a catheter tipped syringe and then add the contents of a 2.5 mg or 5 mg NEXIUM packet. For the 10 mg, 20 mg, and 40 mg strengths, the volume of water in the syringe should be 15 mL. It is important to only use a catheter tipped syringe when administering NEXIUM through a nasogastric tube or gastric tube.
- Immediately shake the syringe and leave 2 to 3 minutes to thicken.
- Shake the syringe and inject through the nasogastric or gastric tube, French size 6 or larger, into the stomach within 30 minutes.
- Refill the syringe with an equal amount of water (5 mL or 15 mL).
- Shake and flush any remaining contents from the nasogastric or gastric tube into the stomach.
Dosage Forms And Strengths
NEXIUM Delayed-Release Capsules, 20 mg - opaque, hard gelatin, amethyst colored capsules with two radial bars in yellow on the cap and NEXIUM 20 mg in yellow on the body.
NEXIUM Delayed-Release Capsules, 40 mg - opaque, hard gelatin, amethyst colored capsules with three radial bars in yellow on the cap and NEXIUM 40 mg in yellow on the body.
NEXIUM For Delayed-Release Oral Suspension, 2.5 mg, 5 mg, 10 mg, 20 mg or 40 mg - unit dose packet containing a fine yellow powder, consisting of white to pale brownish esomeprazole granules and pale yellow inactive granules.
Storage And Handling
NEXIUM Delayed-Release Capsules, 20 mg, are opaque, hard gelatin, amethyst colored capsules with two radial bars in yellow on the cap and NEXIUM 20 mg in yellow on the body. They are supplied as follows:
NDC 0186-5020-31 unit of use
bottles of 30
NDC 0186-5022-28 unit dose packages of 100
NDC 0186-5020-54 bottles of 90
NDC 0186-5020-82 bottles of 1000
NEXIUM Delayed-Release Capsules, 40 mg, are opaque, hard gelatin, amethyst colored capsules with three radial bars in yellow on the cap and NEXIUM 40 mg in yellow on the body. They are supplied as follows:
NDC 0186-5040-31 unit of use
bottles of 30
NDC 0186-5042-28 unit dose packages of 100
NDC 0186-5040-54 bottles of 90
NDC 0186-5040-82 bottles of 1000
NDC 0186-5040-35 unit of use bottles of 30
NDC 0186-5042-25 unit dose packages of 100
NDC 0186-5040-55 bottles of 90
NDC 0186-5040-85 bottles of 1000
NEXIUM For Delayed-Release Oral Suspension is supplied as a unit dose packet containing a fine yellow powder, consisting of white to pale brownish esomeprazole granules and pale yellow inactive granules. NEXIUM unit dose packets are supplied as follows:
NDC 0186-4025-01 unit dose
packages of 30: 2.5mg packets
NDC 0186-4050-01 unit dose packages of 30: 5 mg packets
NDC 0186-4010-01 unit dose packages of 30: 10 mg packets
NDC 0186-4020-01 unit dose packages of 30: 20 mg packets
NDC 0186-4040-01 unit dose packages of 30: 40 mg packets
Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F). [See USP Controlled Room Temperature]. Keep NEXIUM Delayed-Release Capsules container tightly closed. Dispense in a tight container if the NEXIUM Delayed-Release Capsules product package is subdivided.
Distributed by: AstraZeneca LP Wilmington, DE 19850. Rev. 02/2014This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 3/11/2014
Additional Nexium Information
Nexium - User Reviews
Nexium User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.